Kelley R Jordan1, Cory R Wyatt2, Meghan E Fallon1, Randy Woltjer3, Edward A Neuwelt4, Quifang Cheng5,6, David Gailani5,6, Christina Lorentz1,7, Erik I Tucker1,7, Owen J T McCarty1, Monica T Hinds1, Khanh P Nguyen1,8. 1. Department of Biomedical Engineering, School of Medicine, Portland, Oregon, USA. 2. Advanced Imaging Research Center, Portland, Oregon, USA. 3. Department of Pathology, Portland, Oregon, USA. 4. Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA. 5. Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. 6. Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, USA. 7. Aronora Inc., Portland, Oregon, USA. 8. VA Portland Health Care System, Portland, Oregon, USA.
Abstract
BACKGROUND: Deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS) remain highly prevalent despite modern medical therapy. Contact activation is a promising target for safe antithrombotic anticoagulation. The anti-factor XI (FXI) monoclonal antibody 14E11 reduces circulating levels of FXI without compromising hemostasis. The human recombinant analog, AB023, is in clinical development. The role of FXI in mediation of inflammation during DVT resolution is unknown. OBJECTIVES: Investigate the effects of pharmacological targeting of FXI with 14E11 in an experimental model of venous thrombosis. METHODS: Adult wild-type CD1 mice were treated with subcutaneous anti-FXI antibody (14E11, 5 mg/kg) versus saline prior to undergoing surgical constriction of the inferior vena cava (IVC). Mice were evaluated at various time points to assess thrombus weight and volume, as well as histology analysis, ferumoxytol enhanced magnetic resonance imaging (Fe-MRI), and whole blood flow cytometry. RESULTS: 14E11-treated mice had reduced thrombus weights and volumes after IVC constriction on day 7 compared to saline-treated mice. 14E11 treatment reduced circulating monocytes by flow cytometry and macrophage content within thrombi as evaluated by histologic staining and Fe-MRI. Collagen deposition was increased at day 3 while CD31 and smooth muscle cell actin expression was increased at day 7 in the thrombi of 14E11-treated mice compared to saline-treated mice. CONCLUSION: Pharmacologic targeting of FXI enhances the early stages of experimental venous thrombus resolution in wild-type CD1 mice, and may be of interest for future clinical evaluation of the antibody in DVT and PTS.
BACKGROUND: Deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS) remain highly prevalent despite modern medical therapy. Contact activation is a promising target for safe antithrombotic anticoagulation. The anti-factor XI (FXI) monoclonal antibody 14E11 reduces circulating levels of FXI without compromising hemostasis. The human recombinant analog, AB023, is in clinical development. The role of FXI in mediation of inflammation during DVT resolution is unknown. OBJECTIVES: Investigate the effects of pharmacological targeting of FXI with 14E11 in an experimental model of venous thrombosis. METHODS: Adult wild-type CD1 mice were treated with subcutaneous anti-FXI antibody (14E11, 5 mg/kg) versus saline prior to undergoing surgical constriction of the inferior vena cava (IVC). Mice were evaluated at various time points to assess thrombus weight and volume, as well as histology analysis, ferumoxytol enhanced magnetic resonance imaging (Fe-MRI), and whole blood flow cytometry. RESULTS: 14E11-treated mice had reduced thrombus weights and volumes after IVC constriction on day 7 compared to saline-treated mice. 14E11 treatment reduced circulating monocytes by flow cytometry and macrophage content within thrombi as evaluated by histologic staining and Fe-MRI. Collagen deposition was increased at day 3 while CD31 and smooth muscle cell actin expression was increased at day 7 in the thrombi of 14E11-treated mice compared to saline-treated mice. CONCLUSION: Pharmacologic targeting of FXI enhances the early stages of experimental venous thrombus resolution in wild-type CD1 mice, and may be of interest for future clinical evaluation of the antibody in DVT and PTS.
Authors: Michael Iv; Peyman Samghabadi; Samantha Holdsworth; Andrew Gentles; Paymon Rezaii; Griffith Harsh; Gordon Li; Reena Thomas; Michael Moseley; Heike E Daldrup-Link; Hannes Vogel; Max Wintermark; Samuel Cheshier; Kristen W Yeom Journal: Radiology Date: 2018-11-06 Impact factor: 11.105
Authors: Robert Silasi; Ravi Shankar Keshari; Cristina Lupu; Walter Janse Van Rensburg; Hala Chaaban; Girija Regmi; Aleksandr Shamanaev; Joseph J Shatzel; Cristina Puy; Christina U Lorentz; Erik I Tucker; David Gailani; András Gruber; Owen J T McCarty; Florea Lupu Journal: Blood Adv Date: 2019-02-26
Authors: Erik I Tucker; Norah G Verbout; Philberta Y Leung; Sawan Hurst; Owen J T McCarty; David Gailani; András Gruber Journal: Blood Date: 2012-03-22 Impact factor: 22.113
Authors: Emma P DeLoughery; Sven R Olson; Cristina Puy; Owen J T McCarty; Joseph J Shatzel Journal: Semin Thromb Hemost Date: 2019-06-19 Impact factor: 4.180
Authors: B Modarai; J Humphries; K G Burnand; J A Gossage; M Waltham; A Wadoodi; G S Kanaganayagam; A Afuwape; E Paleolog; A Smith Journal: Arterioscler Thromb Vasc Biol Date: 2008-07-31 Impact factor: 8.311
Authors: Steven Y Huang; Charles Y Kim; Michael J Miller; Rajan T Gupta; Mark L Lessne; Jeffrey J Horvath; Daniel T Boll; Paul D Evans; Nicholas T Befera; Pranay Krishnan; Johanna L Chan; Elmar M Merkle Journal: AJR Am J Roentgenol Date: 2013-07 Impact factor: 3.959